An Initial Public Offering, or IPO, is a company’s first-ever share sale to the general public with the goal of raising capital for expansion. IPOs come in two varieties: mainboard IPOs and SME ...

Under the terms of the six-year agreement, Emergent will add KLOXXADO® Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.

“Meeting the needs of our patients and customers by now offering two nasal naloxone products at different strengths – NARCAN ® Nasal Spray 4 mg and KLOXXADO ® Nasal Spray 8 mg – allows ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...